Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted they announced they will acquire Opus Genetics in all-stock transaction, gaining seven gene therapy programs for inherited retinal disease and will trade under a new symbol “IRD” on October 24th.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: